{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:58:32Z","timestamp":1769903912457,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005445","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":409,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005445.pub2","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T17:26:15Z","timestamp":1263835575000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ribavirin plus interferon versus interferon for chronic hepatitis C"],"prefix":"10.1002","author":[{"given":"Jesper","family":"Brok","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0001|cit1","first-page":"267A","article-title":"Treatment of severe hepatitis C: interferon + ribavirine vs interferon (abstract)","volume":"30","author":"Abergel","year":"1999","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD005445.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/00042737-200411000-00022","article-title":"Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis","volume":"16","author":"Abergel","year":"2004","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0003|cit3","first-page":"468A","article-title":"Treatment of severe chronic hepatitis C (CHC) interferon (IFN) versus IFN + ribavirine (Riba). Preliminary results of a prospective study (abstract)","volume":"26","author":"Abergel","year":"1997","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD005445.pub2-BIB0004|cit4","first-page":"688","article-title":"Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study","volume":"31","author":"Andreone","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0005|cit5","first-page":"119A","article-title":"A randomized controlled trial of IFN alfa+ketoprofen or IFN alfa+ribavirin in HCV chronic active hepatitis (CAH) non-responder to IFN-alfa alone (abstract)","volume":"22","author":"Andreone","year":"1995","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0006|cit6","first-page":"94A","article-title":"IFN- alpha plus ketoprofen or ribavirin in HCV-positive chronic active hepatitis (CAH) non-responder to IFN-alpha alone: results of a randomized trial (abstract)","volume":"23 Suppl 1","author":"Andreone","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0007|cit7","first-page":"216A","article-title":"IFNalfa-n3 vs IFNalfa-n3 plus ribavirin in chronic hepatitis C (CHC) resistant to other IFNalfa treatments: results of a randomized multicenter trial (abstract)","volume":"26","author":"Andreone","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0008|cit8","first-page":"90","article-title":"A randomized controlled trial of leukocytic IFN-a vs. leukocytic IFN-a plus ribavirin in chronic hepatitis C resistant to a previous recombinant or lymphoblastoid IFN treatment","volume":"29","author":"Andreone","year":"1997","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0168-8278(99)80130-5","article-title":"Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial","volume":"30","author":"Andreone","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/jhep.2001.26086","article-title":"A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta","volume":"34","author":"Asahina","year":"2001","journal-title":"Hepatology."},{"key":"10.1002\/14651858.CD005445.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"198A","DOI":"10.1016\/S0168-8278(98)80968-9","article-title":"Interferon plus ribavirin vs interferon alone in HCV chronic liver disease non responder to a previous cycle of interferon alone (abstract)","volume":"28 Suppl 1","author":"Ascione","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD005445.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1572-0241.1998.00702.x","article-title":"Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study","volume":"93","author":"Barbaro","year":"1998","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0013|cit13","first-page":"476A","article-title":"Alpha interferon 2b plus ribavirin in CHC relapser or not responder patients to alpha interferon 2b alone: an Italian multicenter randomized controlled clinical study (abstract)","volume":"28","author":"Barbaro","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0014|cit14","first-page":"116A","article-title":"Alpha interferon 2b plus ribavirin in CHC relapser or not responder patients to alpha interferon 2b alone: an Italian multicenter randomized, controlled clinical study (abstract)","volume":"30","author":"Barbaro","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(99)00160-6","article-title":"Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial","volume":"107","author":"Barbaro","year":"1999","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(00)80281-0","article-title":"Evaluation of efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience","volume":"33","author":"Barbaro","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/00365529950173087","article-title":"Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a","volume":"34","author":"Bell","year":"1999","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up","volume":"8","author":"Dalgard","year":"2002","journal-title":"European Addiction Research"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2893.1997.00142.x","article-title":"Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial","volume":"4","author":"Bellobuono","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0020|cit20","first-page":"82A","article-title":"Retreatment of chronic hepatitis C with ribavirin and alpha interferon: a randomized controlled study in non-responder or relapser patients (abstract)","volume":"25 Suppl 1","author":"Bellobuono","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0021|cit21","first-page":"263A","article-title":"Twelve month retreatment with IFN and ribavirin or IFN alone in relapser patients with chronic hepatitis C (abstract)","volume":"30","author":"Bellobuono","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0168-8278(00)80283-4","article-title":"Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy","volume":"33","author":"Bellobbuono","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(98)80640-5","article-title":"Significant improvement of virological response after ribavirin addition to IFN in still viremic patients after the initial month of IFN therapy for chronic hepatitis C (abstract)","volume":"28","author":"Bellobuono","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0024|cit24","first-page":"115","article-title":"Effiacy of ribavirin addition to alpha IFN after the initial month of therapy in unresponsive patients: relationship with HCV RNA titre and HCV genotype (abstract)","volume":"30","author":"Bellobuono","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1034\/j.1600-0676.2000.020006427.x","article-title":"Efficacy of a short-term ribavirin plus interferon alfa combination therapy followed by interferon alfa alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial","volume":"20","author":"Berg","year":"2000","journal-title":"Liver"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0026|cit26","first-page":"70","article-title":"Efficacy of short-term induction therapy with ribavirin plus interferon alfa in previously untreated patients with chronic hepatitis C (abstract)","volume":"30","author":"Berg","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0027|cit27","first-page":"373A","article-title":"Efficacy of short-term ribavirin plus interferon alfa combination therapy followed by interferon alfa alone in previously untreated patients with chronic hepatitis C. A randomized trial (abstract)","volume":"28","author":"Berg","year":"1998","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD005445.pub2-BIB0028|cit28","first-page":"715","article-title":"Interferon-antibodies and the breakthrough phenomenon during ribavirin\/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C","volume":"37","author":"Hoffmann","year":"1999","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0168-8278(98)80357-7","article-title":"Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C","volume":"28","author":"Hoffmann","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep.510280132","article-title":"Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover","volume":"28","author":"Zeuzem","year":"1998","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-2000-10299","article-title":"Influence of ribavirin on the dynamics of hepatitis C viremia in Interferon-alpha-treated Patients with response or nonresponse","volume":"38","author":"Berg","year":"2000","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0032|cit32","first-page":"373A","article-title":"Kinetics of hepatitis C viremia in interferon plus ribavirin treated patients (abstract)","volume":"28","author":"Berg","year":"1998","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0168-8278(01)80613-9","article-title":"High rate long term response after one year interferon plus ribavirin treatment for hepatitis C relapsers. Results of a controlled randomised study in 191 patients (abstract)","volume":"34 Suppl 1","author":"Boucher","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1600-0676.2003.00836.x","article-title":"High rate of long-term virological response after a 1-year course of interferon +\/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial","volume":"23","author":"Boucher","year":"2003","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1590-8658(00)80334-5","article-title":"High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon","volume":"32","author":"Bresci","year":"2000","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2893.2000.00212.x","article-title":"Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon","volume":"7","author":"Bresci","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0037|cit37","first-page":"395A","article-title":"Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alpha combination therapy: evidence for long-term efficacy and safety (abstract)","volume":"24","author":"Brillanti","year":"1996","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0039|cit39","first-page":"101","article-title":"Ribavirin combined with alpha interferon treatment for chronic HCV infection resistant to alpha interferon therapy (abstract)","volume":"18","author":"Brillanti","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0040|cit40","first-page":"13","article-title":"Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience","volume":"23","author":"Brillanti","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0041|cit41","first-page":"307A","article-title":"Low relapse rate in chronic hepatitis C treated with 18 months interferon-alpha and ribavirin as compared to 6 months combination therapy and to 18 months monotherapy. A Benelux study in 300 patients (abstract)","volume":"32","author":"Brouwer","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2003.12.017","article-title":"Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients","volume":"40","author":"Brouwer","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0168-8278(01)80048-9","article-title":"Reduction of relapse in chronic HCV: a Benelux study in 300 patients","volume":"34","author":"Brouwer","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-230X-3-24","article-title":"Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux","volume":"29;3","author":"Veldt","year":"2003","journal-title":"BMC Gastroenterolology"},{"issue":"Suppl","key":"10.1002\/14651858.CD005445.pub2-BIB0045|cit45","first-page":"F83","article-title":"Results of associated treatment with interferon (IFN) + ribavirin in HCV active chronic hepatitis (abstract)","volume":"15","author":"Bugliescu","year":"2000","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0046|cit46","first-page":"395A","article-title":"A randomised controlled trial of leukocyte IFN-alpha+ribavirin in HCV chronic hepatitis relapsing patients (abstract)","volume":"24","author":"Caremani","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0168-8278(00)80169-5","article-title":"The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group","volume":"33","author":"Cavalletto","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0168-8278(98)80628-4","article-title":"Retreatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination (IFN-RIBA) therapy (abstract)","volume":"28","author":"Chemello","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"1128","key":"10.1002\/14651858.CD005445.pub2-BIB0049|cit49","first-page":"103","article-title":"Interferon-alpha 2a\/Ribavirin versus interferon-alpha 2a alone for the retreatment of hepatitis C patients who relapse after standard course of interferon","volume":"114","author":"Chapman","year":"2001","journal-title":"The New Zealand Medical Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0050|cit50","first-page":"8","article-title":"The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C","volume":"23","author":"Chemello","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0051|cit51","first-page":"12","article-title":"Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes (abstract)","volume":"21","author":"Chemello","year":"1994","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1590-8658(02)80255-9","article-title":"Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C","volume":"34","author":"Cheng","year":"2002","journal-title":"Digestive and Liver Disease"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1478-3231.2004.0954.x","article-title":"Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan","volume":"24","author":"Chuang","year":"2004","journal-title":"Liver International"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0054|cit54","first-page":"274A","article-title":"Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone (abstract)","volume":"26","author":"Davis","year":"1997","journal-title":"Hepatology"},{"issue":"21","key":"10.1002\/14651858.CD005445.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C","volume":"339","author":"Davis","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0056|cit56","first-page":"77","article-title":"Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients","volume":"19","author":"Neary","year":"1999","journal-title":"Seminars in Liver Disease"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: impact of disease and treatment response","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0058|cit58","first-page":"758","article-title":"Interferon-alpha-2b for retreatment of chronic hepatitis C","volume":"49","author":"Dettmer","year":"2002","journal-title":"Hepato-gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0059|cit59","first-page":"201A","article-title":"Multicenter placebo-controlled, double-blind trial of interferon alpha-2b plus ribavirin vs. interferon alone for retreatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon: a 48 week review (abstract)","volume":"30","author":"Dettmer","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005445.pub2-BIB0060|cit60","first-page":"703A","article-title":"Double-blind placebo-controlled trial of interferon alpha-2b plus ribavirin versus interferon alpha-2b for retreatment of patients with chronic hepatitis C who failed previous treatment with interferon alpha (abstract)","volume":"28","author":"Sarabanchong","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(01)80523-7","article-title":"Pegylated (40 KDA) interferon alfa-2A (PEGASYS) in new combination therapies: A report of a randomized, multicenter efficacy and safety study (abstract)","volume":"34","author":"Bisceglie","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0062|cit62","first-page":"472","article-title":"Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients","volume":"31","author":"el-Zayadi","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0063|cit63","first-page":"415A","article-title":"A prospective, randomized controlled trial of high dose interferon-alfa plus ribavirin in interferon-nonresponders with chronic hepatitis C (abstract)","volume":"26","author":"Ferenci","year":"1997","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2893.1999.00005.x","article-title":"Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alfa in interferon nonresponders with chronic hepatitis C","volume":"1","author":"Ferenci","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00042737-200106000-00014","article-title":"Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomised trial","volume":"13","author":"Ferenci","year":"2001","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD005445.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/jhep.2002.35529","article-title":"Hepatitis in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1665-2681(19)32139-8","article-title":"Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial","volume":"2","author":"Bosques-Padilla","year":"2003","journal-title":"Annals of Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD005445.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C viral infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2003.12.014","article-title":"The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C","volume":"40","author":"Hassanein","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD005445.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1128\/JVI.73.9.7241-7247.1999","article-title":"Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C","volume":"73","author":"Gerotto","year":"1999","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/jhep.2000.16661","article-title":"A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C","volume":"32","author":"Glue","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0072|cit72","first-page":"705A","article-title":"HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) wirth or without ribavirin in IFN-naive genotype 1 chronic HCV patients","volume":"42","author":"Gorbakov","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-007-2006-3","article-title":"A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C","volume":"42","author":"Gramenzi","year":"2007","journal-title":"Journal of Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0074|cit74","first-page":"634A","article-title":"Interferon alpha 2b 5MU tiw with or without ribavirin as initial treatment for hepatitis C (abstract)","volume":"30","author":"Gross","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0075|cit75","first-page":"634A","article-title":"Interferon alpha 2b 5MIU tiw,+\/- 4-week daily interferon induction, +\/- ribavirin, for re-treatment of interferon non-responders with chronic hepatitis C (abstract)","volume":"30","author":"Gross","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0076|cit76","first-page":"364A","article-title":"A comparison of standard and induction interferon therapy with and without initial ribavirin in treatment naive patients with chronic hepatitis C (abstract)","volume":"32","author":"Peine","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10620-005-2563-3","article-title":"Peginterferon alfa-2a combination therapies in chronic hepatitis C patients who relapsed after or had viral breakthrough on therapy with standard interferon alfa-2b plus ribavirin: a pilot study of efficacy an safety","volume":"50","author":"Herrine","year":"2005","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(08)60060-4","article-title":"Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study","volume":"48","author":"Dusheiko","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0079|cit79","first-page":"268A","article-title":"Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C, first interim analysis","volume":"46","author":"Hezode","year":"2007","journal-title":"Hepatology"},{"issue":"18","key":"10.1002\/14651858.CD005445.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and Peginterferon with or withoutRibavirin for Chronic HCV Infection","volume":"360","author":"Hezode","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions","volume":"46","author":"Khakoo","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1600-0676.2000.020004335.x","article-title":"Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis","volume":"20","author":"Koshy","year":"2000","journal-title":"Liver"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1440-1746.2007.04834.x","article-title":"Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients","volume":"22","author":"Kuboki","year":"2007","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/gast.1996.v111.pm8898645","article-title":"Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C","volume":"111","author":"Lai","year":"1996","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"93A","DOI":"10.1016\/0270-9139(93)91900-D","article-title":"Combination therapy of alfa-interferon and ribavirin in patients with chronic hepatitis C: an interim report (abstract)","volume":"18","author":"Lai","year":"1993","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0168-8278(02)00026-0","article-title":"Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis","volume":"36","author":"L\u00e9dinghen","year":"2002","journal-title":"Journal of Hepatatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0087|cit87","first-page":"374A","article-title":"Retreatment for chronic hepatitis C interferon non-responsders patients. Preliminary results of a multicenter randomised controlled trial of interferon plus ribavirin versus interferon alone (abstract)","volume":"28","author":"L\u00e9dinghen","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0168-8278(02)00071-5","article-title":"Daily or three times per week interferon alpha-2b combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone","volume":"36","author":"L\u00e9dinghen","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2036.2002.01201.x","article-title":"A randomised trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon","volume":"16","author":"Malik","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0090|cit90","first-page":"137","article-title":"End of therapy response in naive pts: 6MU IFN alpha 2B+ribavirin vs IFN alpha 2B 6MU alone (abstract)","volume":"30","author":"Mangia","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0168-8278(00)00024-6","article-title":"Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomised controlled trial","volume":"34","author":"Mangia","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0092|cit92","first-page":"192A","article-title":"Randomized controlled trial of combination therapy with interferon (IFN) alfa-2A and ribavirin, in patients with chronic hepatitis C who relapsed after interferon therapy (abstract)","volume":"30","author":"Marcellin","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0093|cit93","first-page":"333A","article-title":"Early Viral clearance and sustained response in chronic Hepatitis C: The effect of adding ribavirin after high dose IFN induction (abstract)","volume":"4 Pt 2","author":"Marco","year":"2001","journal-title":"Hepatology 2001"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0094|cit94","first-page":"453","article-title":"Early viral clearance and sustained response in chronic hepattis C: a controlled trial of interferon and ribavirin after high-dose interferon induction","volume":"9","author":"Marco","year":"2002","journal-title":"Journal of Viral Hepatitis"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0095|cit95","first-page":"387A","article-title":"Interferon alfa 2B alone or in combination with ribavirin in naive chronic HCV patients: a US multicenter trial (abstract)","volume":"28","author":"McHutchison","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0096|cit96","first-page":"365A","article-title":"Predicting response to initial therapy with interferon alfa during ribavirin in chronic hepatitis C using serum HCV RNA during therapy (abstract)","volume":"30","author":"McHutchison","year":"1999","journal-title":"Hepatology"},{"issue":"21","key":"10.1002\/14651858.CD005445.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0168-8278(00)00026-X","article-title":"The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity","volume":"34","author":"McHutchison","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0099|cit99","first-page":"309A","article-title":"Early prediction and mechanism of the ribavirin\/IFN-aloha dual therapy effect on chronic hepatitis C virus (HCV) infection (abstract)","volume":"30","author":"Neumann","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0100|cit100","first-page":"193A","article-title":"The inpact of therapy with interferon alfa 2B plus ribavirin on health related quality of life and work productivity in chronic hepatitis C patients (abstract)","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0101|cit101","first-page":"181","article-title":"Ribavirin plus IFN vs IFN alone in the treatment of either non-responder or relapser patients with chronic hepatitis C (abstract)","volume":"26","author":"Milella","year":"1997","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0102|cit102","first-page":"211","article-title":"Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone","volume":"31","author":"Milella","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0103|cit103","first-page":"199A","article-title":"Double-blind placebo controlled study of interferon versus interferon plaus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy (abstract)","volume":"30","author":"Nunes","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0104|cit104","first-page":"288A","article-title":"Early changes in HCV hypervariable region 1 (HVR1) and non structural (NS) 5A gene quasispecies during interferon (IFN)-alpha or ribavirin treatment: clues to the mechanisms of HCV resistance to antiviral therapy (abstract)","volume":"28","author":"Cast\u00e9ra","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0105|cit105","first-page":"288A","article-title":"Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance (abstract)","volume":"28","author":"Pawlotsky","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0168-8278(04)90502-8","article-title":"Peg-interferon alpha-2a monotherapy vs Peg-interferon alpha-2a and ribavirin in naive patients with chronic hepatitis C: preliminary results of the SMIEC 2 trial in patients with early viral clearance on Peg-interferon monotherapy (abstract)","volume":"40","author":"Piccolo","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0168-8278(01)80659-0","article-title":"A multi-center randomised trial to determine the safety and tolerability of combined treatment with ribavirin and infergen for HCV in naive patients abstract","volume":"34","author":"Pockros","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2893.2003.00402.x","article-title":"The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients","volume":"10","author":"Pockros","year":"2003","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0110|cit110","first-page":"356A","article-title":"Ribavirin-interferon vs interferon (2b-IFN) alone in non responders to IFN in chronic hepatitis C (abstract)","volume":"24","author":"Pol","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(99)80157-3","article-title":"A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France","volume":"31","author":"Pol","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/jhep.2000.8089","article-title":"Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype 1b-related chronic hepatitis","volume":"31","author":"Pol","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0114|cit113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2893.2003.00426.x","article-title":"Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study","volume":"10","author":"Portal","year":"2003","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0113|cit114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-8278(00)80705-9","article-title":"Retreatment with interferon-ribavirine according to viremia of interferon responders-relapser patients; French multicenter randomized controlled trial","volume":"32 Suppl 2","author":"Portal","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0115|cit115","first-page":"194A","article-title":"Retreatment with interferon-ribavirine according to viremia of interferon responder-relapser patients: preliminary results of a prospective French multicenter randomized controlled study (abstract)","volume":"30","author":"Portal-Bartolomei","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0116|cit116","first-page":"242","article-title":"Interleukine 6 level normalization during interferon-ribavirin combination therapy in chronic hepatitis C (abstract)","volume":"30","author":"Neuman","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0117|cit117","first-page":"257","article-title":"Serum tumor necrosis factor as predictor of sustained response to alpha interferon-ribavirin combination therapy in chronic hepatitis C (abstract)","volume":"30","author":"Neuman","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0118|cit118","first-page":"595A","article-title":"Serum cytokine levels in patients with chronic hepatitis C are predictive value for the study outcome (abstract)","volume":"30","author":"Neuman","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0119|cit119","first-page":"387A","article-title":"A international randomized trial of interferon alfa-2B and ribavirin (intron A\/rebetol) 48 or 24 weeks vs intron a 48 weeks for first line treatment of chronic hepatitis C (abstract)","volume":"28","author":"Poynard","year":"1998","journal-title":"Hepatology"},{"issue":"9138","key":"10.1002\/14651858.CD005445.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0121|cit121","first-page":"594A","article-title":"Treatment of hepatitis C infection with interferon +\/- ribavirin promoted conversion of TH2 to TH1 cytokine profile and decreased inflammation (abstract)","volume":"30","author":"Rasul","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0122|cit122","first-page":"356A","article-title":"Interferon-alpha and ribavirin versus interferon-alpha alone as therapy for chronic hepatitis C - a randomized double-blind placebo-controlled study (abstract)","volume":"24","author":"Reichard","year":"1996","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00365549850161395","article-title":"Comparison of 3 quantitative HCV RNA assays-accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C","volume":"30","author":"Reichard","year":"1998","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"9096","key":"10.1002\/14651858.CD005445.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0125|cit125","first-page":"474A","article-title":"Antiviral effect of ribavirin plus interferon in chronic hepatitis C (abstract)","volume":"28","author":"Ciccorossi","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0126|cit126","first-page":"395A","article-title":"Combination therapy with interferon alpha and ribavirin in interferon alpha relapsers (abstract)","volume":"24","author":"Ricchiuti","year":"1996","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0127|cit127","first-page":"627A","article-title":"Daily administration of interferon alpha 2b and utility of combination therapy with ribavirin as initial treatment for chronic hepatitis C (abstract)","volume":"30","author":"Ricchiuti","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0128|cit128","first-page":"366A","article-title":"Daily administration of intervention alpha 2b and utility of combination therapy with ribavirin vs. initial treatment for chronic hepatitis C: follow up of patients (abstract)","volume":"32","author":"Ricchiutti","year":"2000","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0129|cit129","first-page":"348A","article-title":"Comparative safety of peginterferon alfa-2a (40 kd) (Pegasys) and pegasys plus ribavirin (COPEGUS): results of the prospective, randomized, multicenter, open label wings safety trial","volume":"40","author":"Rodriguez-Torres","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0130|cit130","unstructured":"Salmeron J Perez-Ruiz M Ruiz-Extremera A Torres C Lavin I Quintero D Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial (abstract) Hepatology 1996 395A"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1478-3231.1999.tb00049.x","article-title":"Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial","volume":"19","author":"Salmeron","year":"1999","journal-title":"Liver"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0132|cit132","first-page":"168","article-title":"Interferon alpha-2a in combination therapies for the treatment of chronic hepatitis C in prior non-responders to interferon monotherapy (abstract)","volume":"38","author":"Salmeron","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0133|cit133","first-page":"634A","article-title":"Efficacy of interferon alone or ribavirin interferon combination in HCV related cirrhosis and chronic hepatitis patients: a randomized controlled trial (abstract)","volume":"30","author":"Sarin","year":"1999","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD005445.pub2-BIB0134|cit134","first-page":"505","article-title":"Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone","volume":"28","author":"Scotto","year":"1996","journal-title":"Italian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00063030-200317040-00007","article-title":"Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b","volume":"17","author":"Scotto","year":"2003","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1023\/A:1023725014751","article-title":"Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial","volume":"6","author":"Senturk","year":"2003","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0137|cit137","first-page":"579A","article-title":"Interferon-alfa induction treatment with or without ribavirin in chronic hepatitis C: A multicenter randomized controlled study (abstract)","volume":"36","author":"Senturk","year":"2002","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD005445.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/j.1572-0241.2000.02321.x","article-title":"Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy","volume":"95","author":"Shiffman","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Pt 2 of 2","key":"10.1002\/14651858.CD005445.pub2-BIB0139|cit139","first-page":"362A","article-title":"PEG-INF alfa-2b as a monotherapy or in combination with ribavirin significantly improve end of treatment response rate in HCV genotype 4 chronic active hepatitis (CAH) patients (abstract)","volume":"36","author":"Shobokshi","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"129A","DOI":"10.1016\/S0168-8278(02)80462-7","article-title":"Efficacy of pegylated (40 KDA) IFN alfa-2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active in Saudi Arabia (abstract)","volume":"36","author":"Shobokshi","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"636A","DOI":"10.1016\/S0270-9139(03)81034-0","article-title":"Combination therapy og Peg-interferon alfa-2a and ribavirin significantly enhances sustained virological and biochemical response rate in chronic hepatitis C genotype 4 in Saudi Arabia (abstract)","volume":"38","author":"Shobokshi","year":"2003","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0142|cit142","first-page":"S92","article-title":"Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients (abstract)","volume":"24","author":"Shobokshi","year":"2003","journal-title":"Saudi Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD005445.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1046\/j.1365-2036.2003.01544.x","article-title":"Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone","volume":"17","author":"Sievert","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hep.510280208","article-title":"Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial","volume":"28","author":"Sostegni","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0168-8278(98)80680-6","article-title":"Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone. Results of a randomized controlled trial","volume":"28","author":"Sostegni","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0168-8278(00)81012-0","article-title":"Early HCV-RNA clearance during daily administration of interferon in combination with ribavirin in naive HCV patients (abstract)","volume":"32","author":"Taliani","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0147|cit147","unstructured":"Taliani G Badolato MC Pasquazzi C Gaeta GB Stornaiuolo G Corti G Daily IFN and ribavirin administration induces early HCV-RNA clearance (abstract) Hepatology 1999 632A"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0148|cit148","first-page":"147","article-title":"IFN alpha-con 1 + riba combination therapy in naive difficult-to-treat patients affected by chronic hepatitis C (abstract)","volume":"34","author":"Tempini","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1386-6346(97)00056-9","article-title":"Ribavirin plus human leucocyte interferon alpha for the treatment of interferon resistant chronic hepatitis C: a controlled trial","volume":"8","author":"Toccaceli","year":"1997","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00063030-200013040-00008","article-title":"Interferon-alfa alone versus interferon-alfa plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alfa treatment","volume":"13","author":"Trippi","year":"2000","journal-title":"BioDrugs"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80739-4","article-title":"Retreatment of chronic hepatitis C patients with previous non-response to interferon alone (abstract)","volume":"32","author":"Vandelli","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200206000-00007","article-title":"High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomised, double blind, placebo controlled trial of interferon alpha-2b with or without ribavirin","volume":"14","author":"Verbaan","year":"2002","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005445.pub2-BIB0153|cit153","first-page":"283A","article-title":"High dose interferon alfa-2b (IFN) with or without ribavirin (RIB) for chronic hepatitis C in non-responders to standard therapy (abstract)","volume":"28","author":"Wood","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(00)80745-X","article-title":"High response rates to interferon induction plus ribavirin and amantadine in the treatment of interferon nonresponder chronic hepatitis C patients: a randomized controlled pilot study (abstract)","volume":"32","author":"Adinolfi","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD005445.pub2-BIB0155|cit155","first-page":"1227","article-title":"Treatment of chronic viral hepatitis in Hungary","volume":"140","author":"Alajos","year":"1999","journal-title":"Orvosi Hetilap"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-8278(00)80775-8","article-title":"High dose of interferona (IFN) plus ribavirin (RIBA) for 6 or 12 months in non responder (NR) patients with chronic hepatitis C (CHC): Results of a randomized trial (abstract)","volume":"32","author":"Andreone","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0157|cit157","first-page":"635A","article-title":"Preliminary results of a nynest interferon-ribavirin treatment trials in chronic hepatitis C patients not previously treated with interferon (abstract)","volume":"30","author":"Antignano","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0158|cit158","first-page":"372A","article-title":"Interferon-ribavirin combination is successful in eliminating hepatitis C virus in non-responders to interferon alone including patients with normal aminotransferases (abstract)","volume":"28","author":"Bacon","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0159|cit159","first-page":"476A","article-title":"A preliminary study of short course of ribavirin and alpha interferon in treatment of chronic active hepatitis C not responding to alpha interferon alone (abstract)","volume":"26","author":"Bailey","year":"1997","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(00)80742-4","article-title":"Randomized trial of combination therapy in relapser or non-responder HCV patients (abstract)","volume":"32","author":"Baracetti","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8278(00)80720-5","article-title":"Effect of daily versus twice daily high dose IFN and ribavirin treatment on HCV kinetics (abstract)","volume":"32","author":"Bekkering","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005445.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"A1033","DOI":"10.1016\/0016-5085(95)28434-6","article-title":"Ribavirin followed by alpha interferon in chronic hepatitis C resistant to therapy (abstract)","volume":"108","author":"Bellobuono","year":"1995","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0163|cit163","first-page":"479A","article-title":"Twelwe month combination treatment with ribavirin and alpha IFN in patients affected by chronic hepatitis C unresponsive to alpha IFN: comparison of three different schedules (abstract)","volume":"28","author":"Bellobuono","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-8278(00)81009-0","article-title":"Effect of 12 month aIFN and ribavirin combination therapy in chronic hepatitis C unresponsive to aIFN (abstract)","volume":"32","author":"Bellobbuono","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0168-8278(00)80761-8","article-title":"aIFN and ribavirin combination therapy reduces the occurrence of breakthrough in chronic hepatitis C (abstract)","volume":"32","author":"Bellobuono","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0166|cit166","first-page":"158","article-title":"Ribavirin plus alfa interferon in the treatment of chronic hepatitis C unresponsive to alfa interferon alone. Evaluation of response in terms of ALT values and quantitative viraemia (abstract)","volume":"25","author":"Benetti","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0167|cit167","first-page":"357A","article-title":"IFN alpha 2B and ribavirin in naive patients with HCV type 1 chronic hepatitis: results after 6 months threapy (abstract)","volume":"34","author":"Benetti","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(00)81043-0","article-title":"Interferon\/ribavirin combination therapy witth and without daily dosing in retreatment of chronic hepatitis C (abstract)","volume":"32","author":"Bernatik","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0169|cit169","unstructured":"Bernstein DE Khan R Jeffers LJ Reddy KR Schiff ER Low dose ribavirin (RBV) in combination interferon (IFN) for the treatment of hepatitis C non-responder and relapse patients (abstract) Hepatology 1998 702A"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(00)80476-6","article-title":"Rapid viral clearance with IFN-a 2b induction therapy and ribavirin for chronic HCV infection","volume":"32","author":"Bj\u00f8ro","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/003655202753416920","article-title":"Effect of combined interferon-alfa induction therapy and ribavirin on chronic hepatitis C virus infection","volume":"37","author":"Bj\u00f8ro","year":"2002","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0172|cit172","first-page":"207A","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C (abstract)","volume":"20","author":"Bodenheimer","year":"1994","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0174|cit174","first-page":"290A","article-title":"Hepatic iron deposition during ribavirin therapy of chronic hepatitis C (abstract)","volume":"22","author":"Fiel","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1309\/2GRW-BQ0E-6KYQ-9GMF","article-title":"Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin","volume":"113","author":"Fiel","year":"2000","journal-title":"American Journal of Clinical Pathology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0176|cit176","first-page":"574A","article-title":"Hemolysis in patients being treated with combination intron A\/ribavirin for chronic hepatitis C (HCV) infection (abstract)","volume":"28","author":"Box","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80738-2","article-title":"IFN-induced psychiatric disorders: Suicid attempts are more frequent immediately after IFN (abstract)","volume":"32","author":"Braconnier","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0178|cit178","first-page":"130","article-title":"Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders","volume":"31","author":"Brillanti","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0168-8278(98)80649-1","article-title":"Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C (abstract)","volume":"28","author":"Brillanti","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0180|cit180","first-page":"367A","article-title":"Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: a pilot randomized controlled study (abstract)","volume":"30","author":"Brillanti","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0181|cit181","first-page":"293A","article-title":"Efficacy and safety of 22 weeks of maintenance therapy with peg-interferon alfa-2a alone versus peg-interferon alfa-2a plus ribavirin in naive patients with chronic hepatitis C and genotype 1 who respond to a 24 week course therapy of peg-interferon alfa-2a plus ribavirin (abstract)","volume":"36","author":"Bronowicki","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0182|cit182","first-page":"103","article-title":"Ribavirin therapy for chronic type C hepatitis (abstract)","volume":"13 Suppl 2","author":"Buti","year":"1991","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0168-8278(05)80590-2","article-title":"Ribavirin therapy in chronic delta hepatitis","volume":"19","author":"Buti","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/jhep.2002.32150","article-title":"Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin","volume":"35","author":"Buti","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(05)80550-1","article-title":"Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon","volume":"19","author":"Camps","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0168-8278(00)81195-2","article-title":"Are platelet count and ALT level markers of liver fibrosis in chronic hepatitis C (CHC) (abstract)","volume":"32","author":"Capretti","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(00)80475-4","article-title":"Should the patients with histologically mild chronic hepatitis C be treated? (abstract)","volume":"32","author":"Cast\u00e9ra","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD005445.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00007890-199905150-00014","article-title":"Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation","volume":"67","author":"Cattral","year":"1999","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0168-8278(00)80724-2","article-title":"Decreased production of interferon-g in patients with chronic hepatitis C treated with ribavirin in combination with interferon-alpha (abstract)","volume":"32","author":"Cepparulo","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0190|cit190","first-page":"477A","article-title":"Sustained response in chronic hepatitis C patients after six months of interferon or interferon and ribavirin (abstract)","volume":"28","author":"Cheinquer","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(02)80364-6","article-title":"Is sustained virologic response durable in patients with chronic hepatitis C treated with interferon alfa with or without ribavirin? (abstract)","volume":"36","author":"Cheinquer","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0168-8278(00)81072-7","article-title":"Racial differences in the response to antiviral therapy for chronic hepatitis C (abstract)","volume":"32","author":"Colantoni","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-8278(00)80892-2","article-title":"Why no all patients with hepatitis C are treated? (abstract)","volume":"32","author":"Crespo","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/jlts.2002.31748","article-title":"A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation","volume":"8","author":"Crippin","year":"2002","journal-title":"Liver Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-8278(98)80684-3","article-title":"Ribavirin and interferon retreatment of HCV chronic patients non responder to interferon (abstract)","volume":"28","author":"Bac","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"Franceschi","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0197|cit197","first-page":"4","article-title":"Ribavirin in the treatment of acute viral hepatitis","volume":"99","author":"Mendon\u00e7a","year":"1982","journal-title":"Revista Paulista de Medicina"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0168-8278(05)80626-9","article-title":"Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C","volume":"21","author":"Bisceglie","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0016-5085(93)90905-R","article-title":"Changes in hepatitis C virus antigen in liver with antiviral therapy","volume":"105","author":"Bisceglie","year":"1993","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"A pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Bisceglie","year":"1992","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD005445.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Biscleglie","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0202|cit202","first-page":"93A","article-title":"Randomized, double blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C (abstract)","volume":"18","author":"Biscleglie","year":"1993","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0168-8278(00)80282-2","article-title":"Combined treatment of relapse of chronic hepatitis C with high-dose alpha2B interferon plus ribavirin for 6 or 12 months","volume":"33","author":"Marco","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"185 Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0205|cit204","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/340199","article-title":"Treatment of hepatitis C and anemia in human immunodeficience virus infected patients","volume":"15","author":"Dieterich","year":"2002","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0204|cit205","first-page":"87","article-title":"Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV","volume":"19","author":"Dieterich","year":"1999","journal-title":"Seminars in Liver Disease"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0168-8278(00)81116-2","article-title":"Efficacy of combination treatment (ribavirin plus interferon) in HCV positive patients. Correlation with the genotype (abstract)","volume":"32","author":"Dimitroulopoulos","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0208|cit208","first-page":"206A","article-title":"Results of a placebo-controlled study of ribavirin in patients with chronic hepatitis C (abstract)","volume":"20","author":"Dusheiko","year":"1994","journal-title":"Hepatology"},{"issue":"Pt 10","key":"10.1002\/14651858.CD005445.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","article-title":"The antiviral compound ribavirin modulates the T helper (Th) 1\/Th2 subset balance in hepatitis B and C virus-specific immune responses","volume":"79","author":"Hultgren","year":"1998","journal-title":"The Journal of General Virology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-8278(00)81028-4","article-title":"Treatment with interferon-a and ribavirin in patients with chronic hepatitis C and persistently normal ALT levels (abstract)","volume":"32","author":"Erhardt","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-8278(00)81066-1","article-title":"IFN-ribavirin combination therapy for patients with HCV-related decompensated cirrhosis (abstract)","volume":"32","author":"Ers\u00f6z","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"234A","DOI":"10.1016\/S0168-8278(02)80839-X","article-title":"Consensus interferon (CIFN) in combination with ribavirin for naive patients with chronic hepatitis C (abstract)","volume":"36","author":"Fattovich","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0168-8278(03)00391-X","article-title":"A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"39","author":"Fattovich","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0168-8278(00)81104-6","article-title":"The efficacy of combined interferon-alfa-2B and ribavirin therapy in patients with chronic hepatitis C. Final reports of a multicenter study with 100 patients in Hungary (abstract)","volume":"32","author":"Feher","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0215|cit215","first-page":"183","article-title":"A prospective and randomised study using ribavirin as monotherapy for the treatment of naive patients with chronic hepatitis C","volume":"4","author":"Felipe","year":"2000","journal-title":"Brazilian Journal of Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(00)80477-8","article-title":"Interferon (IFN) induction therapy in combination with ribavirin in chronic hepatitis C (abstract)","volume":"32","author":"Ferenci","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0217|cit217","first-page":"123","article-title":"Effect of initial interferon dosing and dose on early response to combination therapy with ribavirin in chronic hepatitis C (abstract)","volume":"30","author":"Ferenci","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(00)80727-8","article-title":"Histological and virological evolution of long term response after ribavirin and interferon-a combination (abstract)","volume":"32","author":"Fontaine","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0168-8278(00)81004-1","article-title":"Chronic HCV infection in pregnant women (abstract)","volume":"32","author":"Fraquelli","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(00)80744-8","article-title":"Retreatment with IFN alfa 2B + ribavirin (24 vs 48 weeks) for patients with chronic hepatitis C who relapsed or did not respond to IFN alone (abstract)","volume":"32","author":"Gallego","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0221|cit221","first-page":"293A","article-title":"A randomised study of the safety and efficacy of ribavirin vs interferon monotherapy for recurrent HCV infection in liver transplant recipients (abstract)","volume":"24","author":"Gane","year":"1996","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.510270530","article-title":"A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation","volume":"27","author":"Gane","year":"1998","journal-title":"Hepatology"},{"issue":"1-2","key":"10.1002\/14651858.CD005445.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0041-1345(96)00100-5","article-title":"Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients","volume":"29","author":"Garnier","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0224|cit224","first-page":"419","article-title":"Treatment of acute viral hepatitis with ribavirin","volume":"40","author":"Ghamande","year":"1992","journal-title":"The Journal of the Association of Physicians of India."},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0225|cit225","first-page":"574A","article-title":"A randomized trial of interferon alfa-2b, daily vs. three times a week for one month, followed by three times a week for one year in combination with ribavirin in patients who have failed a previous course of interferon (abstract)","volume":"28","author":"Gish","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2893.1997.tb00211.x","article-title":"Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy","volume":"4","author":"Gonzalez-Peralta","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0168-8278(00)81038-7","article-title":"Reliability, validity, and scaling of fatigue severity scales for patients with chronic hepatitis C","volume":"32","author":"Green","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0041-1345(98)00554-5","article-title":"Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin","volume":"30","author":"G\u00f6tz","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0168-8278(00)80706-0","article-title":"Signs and symptoms of liver disease after 10 years of infection with hepatitis C virus. Data from a national cohort of patients who acquired their infections on a known date","volume":"32","author":"Harris","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0230|cit230","first-page":"578A","article-title":"Interferon alpha-2b and ribavirin for non-responding and relapsing chronic hepatitis C - an interim analysis (abstract)","volume":"28","author":"Herrine","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8278(00)81061-2","article-title":"Amantadine\/alpha-interferon combination therapy in HCV chronic hepatitis patients non responders to alpha interferon (abstract)","volume":"32","author":"Hurtov\u00e1","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0168-8278(00)81071-5","article-title":"Ribavirin may decrease the effect of oral anticoagulation (abstract)","volume":"32","author":"Jamoletti","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and Safety of Peginterferon-Alpha 2b and Ribavirin Combination Therapy in Children With Chronic Hepatitis C Infection","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005445.pub2-BIB0234|cit234","first-page":"179","article-title":"Histologic observation on intron and ribavirin in the treatment of 22 patients with chronic hepatitis C","volume":"14","author":"Junqing","year":"1996","journal-title":"Chinese Journal of Infectious Diseases"},{"issue":"64","key":"10.1002\/14651858.CD005445.pub2-BIB0235|cit235","first-page":"340","article-title":"Effectiveness of antiviral treatment of patients with chronic hepatitis C","volume":"11","author":"Juszcyk","year":"2001","journal-title":"Polski Merkuriusz Lekarski"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-8278(00)81093-4","article-title":"Combination therapy with interferon alpha-2B and ribavirin in naive patients with chronic hepatitis C (abstract)","volume":"32","author":"Juszezyk","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD005445.pub2-BIB0237|cit237","first-page":"1235","article-title":"The efficacy of combined interferon-alpha 2b and ribavirin therapy in patients with chronic hepatitis C. Interim report in 100 patients","volume":"140","author":"J\u00e1nos","year":"1999","journal-title":"Orvosi Hetilap"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0238|cit238","first-page":"562A","article-title":"Ribavirin AT 600mg QDleads to equivalent viral response rates as Ribavirin at 1200 mg QD in combination therapy for treatment-naive patients with chronic hepatitis C (abstract)","volume":"32","author":"Kaiser","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8278(01)80498-0","article-title":"High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive patients with chronic hepatitis C (abstract)","volume":"34","author":"Kaiser","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0240|cit240","first-page":"68A","article-title":"Effect of ribavirin and IFN-beta therapy for chronic hepatitis B (abstract)","volume":"16","author":"Kakumu","year":"1992","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hep.1840180206","article-title":"Pilot study of ribavirin and interferon-beta for chronic hepatitis B","volume":"18","author":"Kakumu","year":"1993","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0242|cit242","first-page":"245","article-title":"Interferon and ribavirin for the treatment of relapse and nonresponse of chronic hepatitis C (abstract)","volume":"30","author":"Kallinowski","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD005445.pub2-BIB0243|cit243","first-page":"5","article-title":"Peg.interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T-cell responses","volume":"24","author":"Kamal","year":"2004","journal-title":"Liver International"},{"issue":"10","key":"10.1002\/14651858.CD005445.pub2-BIB0244|cit244","first-page":"662","article-title":"Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C","volume":"100","author":"Kao","year":"2001","journal-title":"Journal of the Formosan Medical Association"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-8278(00)81051-X","article-title":"Combination treatment with interferon (IFN) and ribavirin (RBV) in HCV (+) HIV (-) haemophilia Pts., non responders (NR) to IFN monotherapy (abstract)","volume":"32","author":"Katsarou","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0246|cit246","first-page":"356A","article-title":"Peripheral TH1 and TH2 cytokine responses in patients with HCV treated with interferon and interferon-ribavirin (abstract)","volume":"30","author":"Keaveney","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0247|cit247","first-page":"169A","article-title":"A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non-responders with chronic hepatitis C (abstract)","volume":"28","author":"Khalili","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1572-0241.2000.02025.x","article-title":"Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C","volume":"95","author":"Khalili","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD005445.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/S0041-1345(97)00715-X","article-title":"Hepatitis C recurrence in liver transplant recipients","volume":"29","author":"Kizilisik","year":"1997","journal-title":"Transplantion Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00004836-200207000-00017","article-title":"Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone","volume":"35","author":"Koshy","year":"2002","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jmv.1890450106","article-title":"Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients","volume":"45","author":"Koskinas","year":"1995","journal-title":"Journal of Medical Virology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(00)80762-X","article-title":"High daily dosing interferon-alpha in monotherapy, double and triple therapy of hepatitis C nonresponder patients (abstract)","volume":"32","author":"Kullig","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-8278(00)80768-0","article-title":"H63D HFE gene mutation is a positive predictive factor to response to antiviral therapy in chronic hepatitis C (abstract)","volume":"32","author":"Lebray","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-8278(98)80175-X","article-title":"Effect of ribavirin on virus load and quasispecies distribution in patients","volume":"29","author":"Lee","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0168-8278(00)81015-6","article-title":"Ribavirin: a new treatment of severe and refractory immune thrombocytopenic purpura (ITP) associated with HCV infection? (abstract)","volume":"32","author":"Loustaud-Ratti","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0168-8278(00)81023-5","article-title":"Interferon plus ribavirin dermatological side effects: adding solutions, adding problems (abstract)","volume":"32","author":"Macedo","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0168-8278(02)00140-X","article-title":"High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis","volume":"37","author":"Mangia","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"9286","key":"10.1002\/14651858.CD005445.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0168-8278(00)80282-2","article-title":"Combined treatment of relapse of chronic hepatitis C with high-dose alpha-2b interferon plus ribavirin for 6 or 12 months","volume":"33","author":"Marci","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0260|cit260","first-page":"225A","article-title":"Lack of effect of ribavirin on serum levels of hepatitis C virus (HCV) and hepatitis G virus (HGV) RNA (abstract)","volume":"24","author":"Marrone","year":"1996","journal-title":"Hepatology"},{"issue":"1-2","key":"10.1002\/14651858.CD005445.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0041-1345(96)00248-5","article-title":"Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination","volume":"29","author":"Mazzaferro","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0168-8278(00)81063-6","article-title":"No correlation between the alanine aminotransferase (ALT) levels and the histological activity index (HAI) in patients with chronic hepatitis C (abstract)","volume":"32","author":"Mechkov","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0168-8278(00)81057-0","article-title":"A randomized pilot study in IFN-naive patients comparing daily high-dose interferon-alpha (IFN 2A) triple therapy with tiw interferon-alpha (IFN 2 A ) triple therapy - first results (abstract)","volume":"32","author":"Menzel","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0264|cit264","first-page":"253","article-title":"Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection","volume":"4","author":"Miglioresi","journal-title":"Hepatology Research"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0265|cit265","first-page":"286A","article-title":"Interferon a-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon (abstract)","volume":"28","author":"Min","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0266|cit266","first-page":"192A","article-title":"Interferon a-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon (abstract)","volume":"30","author":"Min","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1572-0241.2001.03692.x","article-title":"Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone","volume":"96","author":"Min","year":"2001","journal-title":"The American Journal of Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0268|cit268","first-page":"677A","article-title":"Over estimation of HCV as a cause of hepatocellular carcinome (HCC). A study in 1948 French patients (abstract)","volume":"30","author":"Mohand","year":"1999","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD005445.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2036.1998.00359.x","article-title":"Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy","volume":"12","author":"Moreno-Monteagudo","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0168-8278(00)80996-4","article-title":"Changes in the oxidative profile during combination therapy (IFNa-2b+ribavirin) in chronic hepatitis C (abstract)","volume":"32","author":"Morisco","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0271|cit271","first-page":"602A","article-title":"Serum tumor necrosis factor levels in chronic hepatitis C (abstract)","volume":"34","author":"Neuman","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00004836-199906000-00006","article-title":"Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report","volume":"28","author":"Nyberg","year":"1999","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0273|cit273","first-page":"286A","article-title":"Hepatitis C viral kinetics treated with ribavirin and interferon alpha-2b in patients with normal transaminases (abstract)","volume":"28","author":"Pena","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.510290135","article-title":"r-Interferon alfa-2b\/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders","volume":"29","author":"Perasso","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0275|cit275","first-page":"146A","article-title":"Therapy with Pegasys demonstrates similar efficacy and significantly improved tolerability, quality of life and work productivity compared with rebetron in patients with chronic hepatitis C","volume":"34","author":"Perrillo","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0168-8278(00)81114-9","article-title":"Efficacy of interferon plus ribavirin therapy in patients with relapsed HCV (abstract)","volume":"32","author":"Petrogiannopoulos","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8278(00)80718-7","article-title":"Reversibility of hepatitis C virus-related (HCV) cirrhosis (abstract)","volume":"32","author":"Pol","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1590-8658(01)80073-6","article-title":"Pilot dose-finding trial of interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone","volume":"33","author":"Puoti","year":"2001","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0279|cit279","first-page":"120","article-title":"Alfa-interferon plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients (abstract)","volume":"30","author":"P\u00e8rez-Olmeda","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0168-8278(00)80773-4","article-title":"IFN plus ribavirin in HIV+patients with chronic hepatitis C (abstract)","volume":"32","author":"P\u00e8rez-Olmeda","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0168-8278(00)80683-2","article-title":"Mechanism of action of ribavirin in treatment of recurrent hepatitis C after liver transplant (abstract)","volume":"32","author":"Quadri","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0282|cit282","first-page":"585","article-title":"Ribavirin treatment of chronic hepatitis c: a phase I study","volume":"16","author":"Rassam","year":"1992","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/978-4-431-68255-4_168","article-title":"Ribavirin or alpha interferon treatment of chronic hepatitis C: assessment of antiviral efficacy","volume":"22","author":"Rassam","year":"1994","journal-title":"Viral Hepatitis and Liver Diseases"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00365549009027087","article-title":"Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis","volume":"22","author":"Reichard","year":"1990","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"8749","key":"10.1002\/14651858.CD005445.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(00)80743-6","article-title":"Long-term follow-up of patients notified with non-A non-B hepatitis in Sweden (1979-84) (abstract)","volume":"32","author":"Reichard","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0168-8278(00)81084-3","article-title":"Feasibility of interferon\/ribavirin-combination therapy in HCV-positive hemodialysis patients (abstract)","volume":"32","author":"Renders","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0168-8278(00)80730-8","article-title":"Interferon-a (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C (CHC): Interim analysis of an ongoing study (SASL 10) (abstract)","volume":"32","author":"Renner-Schneiter","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0289|cit289","first-page":"192A","article-title":"A randomized trial of daily vs b.i.d. interferon induction followed by combination rebetron therapy for HCV genotype 1 infection (abstract)","volume":"30","author":"Rosen","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0290|cit290","first-page":"706A","article-title":"Serum HCV RNA kinetics during combination therapy with daily interferon alpha and ribavirin (abstract)","volume":"28","author":"Rothstein","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0168-8278(00)81109-5","article-title":"Why is the response to combination theraphy in chronic hepatitis C poor? (abstract)","volume":"32","author":"R\u00fdzlov\u00e1","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(00)81037-5","article-title":"Interferon alfa plus ribavirin in chronic hepatitis C relapsers and non-responders to previous interferon alfa course (abstract)","volume":"32","author":"Salmer\u00f3n","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD005445.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/jhep.2002.35442","article-title":"A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy","volume":"36","author":"Saracco","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0168-8278(99)80253-0","article-title":"Improved correlation between multiple mutations within the NS5A region","volume":"30","author":"Sarrazin","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jmv.1890460110","article-title":"Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone","volume":"46","author":"Schvarcz","year":"1995","journal-title":"Journal of Medical Virology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0296|cit296","first-page":"17","article-title":"Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience (abstract)","volume":"23","author":"Schvarcz","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1179\/joc.1995.7.1.58","article-title":"Treatment with ribavirin+alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results","volume":"7","author":"Scotto","year":"1995","journal-title":"Journal of Chemotherapy"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0298|cit298","first-page":"656A","article-title":"Interferon-alpha2b and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C (abstract)","volume":"30","author":"Shakil","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0299|cit299","first-page":"I76","article-title":"Comparison of interferon, ribavirin and combined interferon with ribavirin in chronic hepatitis C with cirrhosis: an interim report","volume":"23","author":"Sherif","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/322778","article-title":"A randomised, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients responded to interferon-ribavirin combination therapy will enhance sustained virologic response","volume":"184","author":"Shiffman","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD005445.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.135.8.1000","article-title":"High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus","volume":"135","author":"Sookoian","year":"1999","journal-title":"Archives of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0168-8278(00)81113-7","article-title":"Hematologic side effects of interferon alpha and ribavirin therapy of chronic active hepatitis C (abstract)","volume":"32","author":"Stalke","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(00)81032-6","article-title":"Successful triple combination treatment of patients with chronic hepatitis C not responding to interferon plus ribavirin","volume":"32","author":"Stauber","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(00)80728-X","article-title":"Retreatment of IFN nonresponders (NR) or relapsers (REL) with chronic hepatitis C with high dose interferon (IFN) in combinatiton with ribavirin (abstract)","volume":"32","author":"Steindl-Munda","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0305|cit305","first-page":"632A","article-title":"Efficacy of interferon-alpha 2b in combination with ribavirin in the treatment if non-responder patients with chronic hepatitis C: a randomised-controlled trial (abstract)","volume":"30","author":"Tassopoulos","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0306|cit306","first-page":"354A","article-title":"Efficacy of daily interferon-alfa-2b in combination with ribavirin in the treatment of non-responder patients with chronic hepatitis C (abstract)","volume":"32","author":"Tassopoulos","year":"2000","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0307|cit307","first-page":"365A","article-title":"Efficacy of daily interferon-alpha-2B (IFN-A) in combination with ribavirin in the treatment of naive patients with chronic hepatitis C (CHC): A randomized controlled trial (abstract)","volume":"23","author":"Tassopoulos","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1046\/j.1365-2141.1997.2953112.x","article-title":"Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients","volume":"98","author":"Telfer","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000007740","article-title":"Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C","volume":"61","author":"Teuber","year":"2000","journal-title":"Digestion"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(00)80763-1","article-title":"Impairment of health-related quality of life in patients with asymptomatic chronic hepatitis B or C in the United Kingdom (abstract)","volume":"32","author":"Thursz","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0311|cit311","first-page":"163","article-title":"Ribavirin in acute viral hepatitis","volume":"37","author":"Tilve","year":"1991","journal-title":"Journal of Postgraduate Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0168-8278(98)81026-X","article-title":"Ribavirin and alpha-interferon in patients with chronic hepatitis C not reponding to interferon alone (abstract)","volume":"28","author":"Tripi","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005445.pub2-BIB0313|cit313","first-page":"478A","article-title":"Four weeks of daily therapy with IFN alpha 2b + ribavirin followed by standard therapy in genotype 3 - results at 12 weeks (abstract)","volume":"28","author":"Tsantoulas","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8278(00)81059-4","article-title":"Retreatment of chronic hepatitis C patients with interferon plus ribavirin vs interferon alone (abstract)","volume":"32","author":"Vandelli","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/00365549950163789","article-title":"Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study","volume":"31","author":"Vega","year":"1999","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0168-8278(00)81112-5","article-title":"Ribavirin and interferon alfa therapy in patients with chronic hepatitis C - preliminary observation (abstract)","volume":"32","author":"Warunek","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8278(00)80719-9","article-title":"Low frequency of cirrhosis in a large hepatitis C outbreak after 20 years (abstract)","volume":"32","author":"Wiese","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0168-8278(01)80508-0","article-title":"Interferon + ribavirin vs interferon alone treatment of children with chronic HCV infection (abstract)","volume":"34","author":"Woynarowsky","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0168-8278(02)80900-X","article-title":"The effect of interferon plus ribavirin or interferon alone on the development of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis C (abstract)","volume":"36","author":"Yang","year":"2002","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0320|cit320","doi-asserted-by":"crossref","unstructured":"Zylberberg H Benhamou Y Chaix ML Fontaine H Rouzioux C Katlama C Efficacy and safety of interferon and ribavirin therapy in HIV-HCV coinfected patients (abstract) Journal of Hepatology 2000 178","DOI":"10.1016\/S0168-8278(00)81007-7"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0321|cit321","first-page":"589A","article-title":"A randomized trial of pegylated interferon alpha-2b and ribavirin vs. pegylated interferon alone in patients with chronic hepatitis C who have failed standard therapy. Interim results after 24 weeks (abstract)","volume":"34","author":"Bornstein","year":"2001","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0322|cit322","first-page":"707A","article-title":"A double blind, placebo controlled crossover trial of high dose interferon combined with ribavirin for hepatitis C infection: preliminary results (abstract)","volume":"28","author":"Clarkston","year":"1998","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0323|cit323","first-page":"316A","article-title":"Early pharmacokinetics and hepatitis C viral kinetics on treatment with pegylted interferon alfa-2a with or without ribavirin: Characterization of the null responder (abstract)","volume":"38","author":"Bisglie","year":"2003","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0324|cit324","first-page":"580A","article-title":"Impact of sustained viral response after IFN-alpha-2b + ribavirin combination therapy or IFN-alpha-2b monotherapy on health-related quality of life in Japanese patients with chronic hepatitis C (abstract)","volume":"34","author":"Fukuhara","year":"2001","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD005445.pub2-BIB0325|cit325","first-page":"A25","article-title":"Six months post treatment follow up comparison of interferon alpha 2b and ribavirin, with interferon 2b alone for one year in chronic HCV infection","volume":"13","author":"Hasnain","year":"1998","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0168-8278(00)81076-4","article-title":"Improvement of quantitative testing of liver function in patients with chronic hepatitis C after initiation of antiviral therapy (abstract)","volume":"32","author":"Herold","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0327|cit327","first-page":"579A","article-title":"High dose induction therapy with IFNalpha-2b + ribavirin is effective in non-responders to previous therapy (abstract)","volume":"34","author":"Iino","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0328|cit328","first-page":"283A","article-title":"African-American response rate to therapy for hepatitis C (abstract)","volume":"28","author":"Fleckenstein","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0329|cit329","first-page":"636A","article-title":"Long term response to interferon and ribavirin for hepatitis C in patients previously treated with interferon alone (abstract)","volume":"30","author":"Ismail","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0330|cit330","first-page":"283A","article-title":"Efficacy of interferon and ribavirin for hepatitis C in patients previously treated with interferon alone (abstract)","volume":"28","author":"Waters","year":"1998","journal-title":"Hepatology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0331|cit331","first-page":"68A","article-title":"Ribavirin and IFN-beta treatment for chronic hepatitis C (abstract)","volume":"16","author":"Kakumu","year":"1992","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0016-5085(93)90727-T","article-title":"A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C","volume":"105","author":"Kakumu","year":"1993","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0333|cit333","first-page":"621A","article-title":"A randomized study of ribavirin plus interferon alfa vs interferon alfa alone for treatment of patients with chronic hepatitis C (abstract)","volume":"30","author":"Lay","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0334|cit334","first-page":"703A","article-title":"Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients (abstract)","volume":"42","author":"Luxon","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0168-8278(00)80701-1","article-title":"Immunological evaluation of ribavirine and interferon-alpha therapy in patients with chronic hepatitis C (abstract)","volume":"32","author":"Pawlowska","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0336|cit336","first-page":"86","article-title":"Different ribavirin interferon combinations in HCV-RNA positive patients non-responders to interferon treatments (abstract)","volume":"25","author":"Persico","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0337|cit337","first-page":"128","article-title":"HCV-RNA dynamics in the first month of treatment with IFN daily therapy alone versus combinations with amantadine or ribavirin (abstract)","volume":"30","author":"Torre","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-8278(00)81006-5","article-title":"Cytokin kinetic and response to interferon a (IFN) alone or in association with amantadine or ribavirin in HCV positive patients (abstract)","volume":"32","author":"Torre","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"134A","DOI":"10.1016\/S0168-8278(02)80481-0","article-title":"Retreatment of chronic hepatitis C patients with previous non response to interferon alone (abstract)","volume":"36","author":"Vandelli","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8278(00)81058-2","article-title":"Viral kinetics in previous IFN-non-responders under IFN-ribavirin-inductions-retherapie (abstract)","volume":"32","author":"Wiese","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0168-8278(00)80755-2","article-title":"Comparison between IFN induction, induction + ribavirin and IFN+ribavirin combination therapy in naive patients with chronic hepatitis C related to genotype 1 (abstract)","volume":"32","author":"Bellobuono","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/1740774507085445","article-title":"Design of the PEDS-C trial: pegylated interferon +\/- ribavirin for children with chronic hepatitis C viral infection","volume":"4","author":"Murray","year":"2007","journal-title":"Clincal trials"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005445.pub2-BIB0343|cit343","first-page":"707A","article-title":"Superiority of induction dosing in the treatment of chronic hepatitis C (abstract)","volume":"28","author":"Sjogren","year":"1998","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(02)80486-X","article-title":"Measurement of viral interferon sensitivity in patients with chronic hepatitis C. Prospective randomised, open label phase 3 clinical trial (abstract)","volume":"36","author":"Vogel","year":"2002","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0345|cit345","unstructured":"Als-Nielsen B Gluud LL Gluud C Methodological quality and treatments effects in randomised trials - a review of six emperical studies (abstract) 12th Cochrane Colloquium, Ottawa, Canada (http:\/\/www.cochrane.org\/colloquia\/abstracts\/ottawa\/) 2004 O 072"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0346|cit346","first-page":"625","article-title":"Epidemiology of hepatitis C","volume":"26","author":"Alter","year":"1997","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.1840360712","article-title":"Prevention of spread of hepatitis C","volume":"36","author":"Alter","year":"2002","journal-title":"Hepatology"},{"issue":"7382","key":"10.1002\/14651858.CD005445.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"22","key":"10.1002\/14651858.CD005445.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1001\/jama.287.22.2973","article-title":"Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials","volume":"287","author":"Balk","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0168-8278(06)80739-7","article-title":"The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy naive patients infected with HCV: phase 3 results (VISER1) (abstract)","volume":"44","author":"Benhamou","year":"2007","journal-title":"Journal of hepatology"},{"issue":"10","key":"10.1002\/14651858.CD005445.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1023\/A:1011919906194","article-title":"Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial","volume":"46","author":"Bonkovsky","year":"2001","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0352|cit352","unstructured":"Brok J Gluud LL Gluud C Ribavirin monotherapy for chronic hepatitis C (Cochrane Review) The Cochrane Library (Submitted for publication)"},{"issue":"8","key":"10.1002\/14651858.CD005445.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C: a systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0355|cit355","first-page":"2","article-title":"Consensus Statement","volume":"11","author":"Unknown","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0356|cit356","article-title":"Another ten stories in antiviral drug discovery (part C): \"Old\" and \"new\" antivirals, strategies, and perspectives","volume":"[Epub ahead of","author":"Clercq","year":"2009","journal-title":"Medical Research Reviews."},{"key":"10.1002\/14651858.CD005445.pub2-BIB0357|cit357","unstructured":"Deeks JJ Bradburn MJ Localio R Berlin J Much ado about nothing: meta-analysis for rare events [abstract] www.ihs.ox.ac.uk\/csm\/talks.html#p23 23"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.gastro.2005.11.011","article-title":"American Gastroenterological Association medical position statement on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"issue":"7109","key":"10.1002\/14651858.CD005445.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/tera.1420170117","article-title":"Teratogenic effects of ribavirin on hamster and rat embryos","volume":"17","author":"Ferm","year":"1978","journal-title":"Teratology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0168-8278(99)80411-5","article-title":"Hepatitis C virus infection: quality of life and side effects of treatment","volume":"31","author":"Foster","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0363|cit363","doi-asserted-by":"crossref","unstructured":"Gebo K Jenckers M Chander G Torbenson MS Ghanem KG Herlong HF Management of chronic hepatitis C (Evidence Report\/Technology Assessment Number 60) Rockvville (MD): Agency for Healthcare Research and Quality (http:\/\/www.ahrq.gov\/clinic\/hepcinv.htm#oral ) 2002 Publ no 02E030","DOI":"10.1037\/e439742005-001"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0365|cit365","unstructured":"Gluud C Nikolova D Klingenberg SL Whitfield K Alexakis N Als-Nielsen B Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 4. Art. No.: LIVER"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0367|cit367","doi-asserted-by":"crossref","unstructured":"Hass HG Nehls O Gregor M Kaiser S Kreysel C Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses Digestive and Liver Diseases 2004 367 8","DOI":"10.1016\/j.dld.2004.01.009"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0369|cit369","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Colloboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: the clinical spectrum of disease","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0371|cit371","unstructured":"Husereau D Basset K Koretz R Interferon-based therapies for chronic hepatitis C virus infection: an assessment of clinical outcomes Ottawa: Canadian Coordinating Office for Health Technology Assessment 2004 Technology report no 47"},{"issue":"3","key":"10.1002\/14651858.CD005445.pub2-BIB0372|cit372","first-page":"546","article-title":"Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials","volume":"104","author":"Keus","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD005445.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0016-5085(00)70381-7","article-title":"Decisions, decisions, decisions","volume":"118","author":"Koretz","year":"2000","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hep.1840360715","article-title":"Introduction to therapy of hepatitis C","volume":"36","author":"Lindsay","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1053\/j.gastro.2007.03.035","article-title":"Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy","volume":"132","author":"Lutchman","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0377|cit377","first-page":"67","article-title":"Safety of combination interferon alfa-2b\/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients","volume":"19","author":"Maddrey","year":"1999","journal-title":"Seminars in Liver Disease"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bmj.318.7193.1256","article-title":"Hepatology","volume":"318","author":"McCarthy","year":"2000","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0381|cit381","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD0003702","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0382|cit382","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Poynard","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Reviews of Infectious Diseases"},{"issue":"9055","key":"10.1002\/14651858.CD005445.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2893.2001.00265.x","article-title":"Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy","volume":"8","author":"Querenghi","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2008.11.006","article-title":"Ribavirin: current role in the optimal clinical management of chronic hepatitis C","volume":"50","author":"Reddy","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0387|cit387","unstructured":"Nordic Cochrane Center Review Manager (RevMan), version 5.0 for Windows 2008"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.510300504","article-title":"The impact of diagnosis of hepatitis C virus on quality of life","volume":"30","author":"Rodger","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005445.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"6","key":"10.1002\/14651858.CD005445.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2036.2003.01494.x","article-title":"Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon","volume":"17","author":"San Miguel","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD005445.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510260704","article-title":"Natural history of hepatitis C","volume":"26","author":"Seeff","year":"1997","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD005445.pub2-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"issue":"33","key":"10.1002\/14651858.CD005445.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4330","article-title":"Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review","volume":"4","author":"Shepherd","year":"2000","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0395|cit395","unstructured":"Siebert U Scroczynski Geman hepatitis C Model Group HTA Expert Panel on Hepatitis C Antiviral combination therapy with interferon\/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment German Medical Science 2003 Doc07"},{"issue":"10","key":"10.1002\/14651858.CD005445.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2036.2007.03294.x","article-title":"Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C","volume":"25","author":"Simin","year":"2007","journal-title":"Alimentary Pharmacology and Therapeutics."},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/gut.50.2.253","article-title":"Cost effectiveness of combination therapy for hepatitis C: a decision analytic model","volume":"50","author":"Stein","year":"2002","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD005445.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0400|cit400","unstructured":"Copenahgen Trial Unit Trial Seuential Analysis, version 0.8 2008"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: impact of disease and treatment response","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0402|cit402","unstructured":"Weis N Krogsgaard K Kjaersgaard LL Keiding H N\u00f8rregaard J Gluud C Chronic hepatitis C. Combination intervention with alfa-interferon and ribavirin Medicinsk Teknologivurdering http:\/\/www.cemtv.dk\/publikationer\/docs\/KroniskHepatitisC\/indhold_til_net.pdf 2002 2"},{"issue":"1","key":"10.1002\/14651858.CD005445.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005445.pub2-BIB0404|cit404","unstructured":"WHO Hepatitis C www.who.int\/mediacentre\/factsheets\/fs164\/en\/"},{"issue":"7644","key":"10.1002\/14651858.CD005445.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005445.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"129A","DOI":"10.1016\/S0168-8278(03)80709-2","article-title":"Interferon alpha plus ribavirin versus interferon alpha for chronic hepatitis C - an updated systematic Cohrane review","volume":"23","author":"Brok","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"19","key":"10.1002\/14651858.CD005445.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/archinte.165.19.2206","article-title":"Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials","volume":"165","author":"Brok","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"7322","key":"10.1002\/14651858.CD005445.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bmj.323.7322.1151","article-title":"Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials","volume":"323","author":"Kjaergard","year":"2002","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD005445.pub2-BIB0409|cit409","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002234.pub2","article-title":"Ribavirin with or without alpha interferon for chronic hepatitis C","author":"Gluud","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005445.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T20:47:25Z","timestamp":1739738845000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005445.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":409,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005445.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}